Kuppusamy Meera; Taib Tarita binti; Asmah Johar; Abdul Manan bin Mat Jais
Volume 19, Issue 3 , 2016, , Pages 67-72
Abstract
Background: Channa striatus or better known as the haruan fish is an indigenous, snakehead, striped, air breathing freshwater fish of Malaysia and has long been consumed traditionally during post-operative and post-partum period to speed recovery. Most medical properties of the haruan are contributed ...
Read More
Background: Channa striatus or better known as the haruan fish is an indigenous, snakehead, striped, air breathing freshwater fish of Malaysia and has long been consumed traditionally during post-operative and post-partum period to speed recovery. Most medical properties of the haruan are contributed to its high content of essential fatty and amino acids. This was a phase I clinical trial to examine the safety of Channa striatus (CS) 5% cream with patch testing and cumulative dosing for up to 4 weeks on the healthy skin. Methods: This double-blind randomized controlled trial was conducted in two stages. Eighty-three participants who fulfilled the inclusion criteria underwent patch testing. The allergens, aqueous and CS 5% cream, were patch tested simultaneously but separately on each arm of the same participant. The participants with a negative patch test started stage 2, whereby they applied randomly assigned creams on both forearms for a duration of 1 month. Results: A total of 83 participants were screened successfully and underwent patch testing. One participant in the cohort developed a positive patch test to CS 5% and was excluded from stage 2. Two participants experienced mild side effects that resolved with mild topical steroid. The incidence of allergic contact dermatitis and irritant contact dermatitis was 1.2% and 2.4% in the participants, respectively. Conclusion: The uniquely Malaysian Channa striatus 5% cream has a good safety profile. Information on the safety and tolerability obtained from this study can be used to design larger phase II studies in patients with inflammatory skin conditions.
Esmaili Nafiseh; Hallaji Zahra; Ehsani Amirhoushang; Tork Ali Naser; Robati RezaMahmood; Toosi Siavash; Zahrian Fatemeh; Maarefat Afsaneh
Volume 10, Issue 2 , 2007, , Pages 100-104
Abstract
Background and aim: Psoriasis is one of the most common inflammatory skin disorders with a genetic background. Several treatment modalities have been used, including systemic and bath PUVA. The aim of this study was to evaluate the efficacy of systemic and bath PUVA in the treatment of psoriasis in Razi ...
Read More
Background and aim: Psoriasis is one of the most common inflammatory skin disorders with a genetic background. Several treatment modalities have been used, including systemic and bath PUVA. The aim of this study was to evaluate the efficacy of systemic and bath PUVA in the treatment of psoriasis in Razi Hospital.Materials and methods: This retrospective database study was done in Razi Hospital and the records of 390 psoriatic patients referred to phototherapy unit in 1999-2003 were studied. One hundred and forty nine patients were treated with systemic and 238 patients with bath PUVA.Results: The most common form of psoriasis was the plaque type and the majority of patients were male. Complete remission of disease was achieved in 20.1% of systemic PUVA and 17.2% of bath PUVA patients, usually after 20-29 sessions of phototherapy. The mean cumulative UVA dose for complete remission was 233.46 and 108.79 J/cm2 in systemic and bath PUVA groups, respectively. Relapse occurred in 33.3% and 17.07% of patients achieving complete remission in systemic and bath PUVA groups, respectively. Erythema was the most common side effect in both groups.Conclusion: Both systemic and bath PUVA are efficacious in the treatment of psoriasis. The total UVA dose needed for complete clearance was higher in systemic PUVA and relapse occurred more frequently in this group.